Homburger advises Santhera on its licensing of AGAMREE® to Nxera Pharma in APAC countries

On January 8, 2026, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had signed an exclusive licensing agreement with Nxera Pharma, a biopharmaceutical company listed on the Tokyo Stock Exchange, for the development, manufacturing and commercialization of AGAMREE^® for the treatment of Duchenne muscular dystrophy in Japan, South Korea, Australia and New Zealand. Santhera will receive a USD 30 m cash upfront payment and a USD 10 m equity investment through the purchase of c. 530 k shares by Nxera at a 20 % premium to the 30-day VWAP.

Homburger advises Santhera on the Swiss corporate, capital markets and financing aspects of the transaction. The Homburger team is led by Daniel Häusermann and includes Marco Rostetter (both Corporate / M&A, Capital Markets) and Eduard De Zordi (Financing, Investment Products, Capital Markets).